Catalan Institute of Oncology, Hospital Duran i Reynals

Barcelona

1 studies enrolling now · 2 studies all time

What they study most

Breast Cancer, MF, Myelofibrosis, Post-ET Myelofibrosis, Post-PV MF, Primary Myelofibrosis

Studies at this site

• Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib — Recruiting now
• Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) — Running, not enrolling